Advertisement
Table 2 Clinicopathologic characteristics of patients based on liver metastatic tumors
| Characteristic | Non-targeted therapy | Bev-combined therapy | Cet-combined therapy |
|---|---|---|---|
| Metastatic tumors | 252 (66.3) | 44 (11.6) | 84 (22.1) |
| Primary tumor site | |||
| Right side | 36 (14.3) | 17 (38.6) | 14 (16.7) |
| Left side | 216 (85.7) | 27 (61.4) | 70 (83.3) |
| Primary tumor grade | |||
| G1–2 | 189 (75.0) | 35 (79.5) | 50 (59.5) |
| G3 | 63 (25.0) | 9 (20.5) | 34 (40.5) |
| Histological subtype of primary tumor | |||
| Non-mucinous | 228 (90.5) | 42 (95.5) | 74 (88.1) |
| Mucinous | 24 (9.5) | 2 (4.5) | 10 (11.9) |
| Primary tumor pT categorya | |||
| pT1–2 | 31 (12.3) | 2 (4.5) | 4 (4.8) |
| pT3–4 | 221 (87.7) | 42 (95.5) | 80 (95.2) |
| Primary tumor pN categorya | |||
| pN0 | 106 (42.1) | 29 (65.9) | 26 (31.0) |
| pN1–2 | 146 (57.9) | 15 (34.1) | 58 (69.0) |
| CEA declineb | |||
| Yes | 136 (54.0) | 35 (79.5) | 55 (65.5) |
| No | 56 (22.2) | 7 (15.9) | 6 (7.1) |
| Unevaluable | 60 (23.8) | 2 (4.5) | 23 (27.4) |
| Metastases presentation | |||
| Synchronous | 208 (82.5) | 40 (90.9) | 67 (79.8) |
| Metachronous | 44 (17.5) | 4 (9.1) | 17 (20.2) |
| Size of metastases (cm) | |||
| < 2.5 | 154 (61.1) | 15 (34.1) | 58 (69.0) |
| ≥ 2.5 | 98 (38.9) | 29 (65.9) | 26 (31.0) |
| Resection status of liver metastases | |||
| R0 | 171 (67.9) | 36 (81.8) | 48 (57.1) |
| R1–2 | 81 (32.1) | 8 (18.2) | 36 (42.9) |
| Duration of preoperative chemotherapyc | |||
| Short duration | 109 (43.3) | 23 (52.3) | 31 (36.9) |
| Long duration | 143 (56.7) | 21 (47.7) | 53 (63.1) |
| Chemotherapy backbone | |||
| Oxa-based | 184 (73.0) | 29 (65.9) | 16 (19.0) |
| Iri-based | 52 (20.6) | 15 (34.1) | 66 (78.6) |
| Oxa + Iri-based | 13 (5.2) | 0 (0.0) | 2 (2.4) |
| Fluoropyrimidine only | 3 (1.2) | 0 (0.0) | 0 (0.0) |
| TRGd | |||
| 1–2 | 95 (37.7) | 21 (47.7) | 32 (38.1) |
| 3 | 97 (38.5) | 15 (34.1) | 32 (38.1) |
| 4–5 | 60 (23.8) | 8 (18.2) | 20 (23.8) |
